NEW YORK (GenomeWeb News) - Oxford Genome Sciences today said it has received an equity placement from three investors, including previous investors South East Growth Fund and Oxford Capital Partners, and first-time investor Catapult Growth Fund.
A company spokesperson declined to disclose the amount of the financing.
OGeS develops disease-related proteins for use in cancer diagnostics and therapeutics.
The company is focusing on antibody therapies that are accompanied by a diagnostic to help guide treatment.